Scleroderma Diagnosis and Evaluation

The diagnosis of systemic sclerosis is a complex clinical undertaking that requires integrating patient history, physical examination, and advanced diagnostic testing. Because the disease can present with a wide variety of symptoms that mimic other autoimmune disorders, rheumatologists rely on a multimodal approach to establish a definitive diagnosis and classify the disease subtype. Early diagnosis is of paramount importance in the era of regenerative medicine, as therapeutic interventions are most effective before irreversible fibrosis has compromised organ function. The classification criteria developed by the American College of Rheumatology and the European Alliance of Associations for Rheumatology serve as the global standard, weighing specific clinical and laboratory features to ensure diagnostic sensitivity.

The diagnostic journey often begins with a high index of suspicion based on the presence of Raynaud’s phenomenon and skin thickening. However, in the early “pre-scleroderma” stage, skin changes may be minimal or absent. In these cases, the physician acts as a detective, looking for the subtle microvascular and serological footprints of the disease. The concept of “Very Early Diagnosis of Systemic Sclerosis” is now a central focus of clinical practice, with sensitive tools used to identify patients at risk of progression, enabling the initiation of vascular and immunomodulating therapies during the critical window of opportunity.